Hardman & Co Investor Forum Research on Shield Therapeutics (STX):
Proactive cash management to cashflow-breakeven
 

Shield is a commercial-stage pharma company delivering specialty products that address the needs of patients with iron deficiency (ID). Since its July 2021 US launch, Shield and Viatris have increased physician awareness of the differentiating characteristics of ACCRUFeR® as an oral ID drug, in order to generate sales traction. The 3Q’24 trading update reiterated the interim statement dialog: sales continue to progress, while costs are being actively managed. Shield is being proactive, extending its working capital financing from $10m to $15m and issuing $10m new shares to AOP, to manage the company through to cashflow-breakeven in 2H’25.
 

Please click on the link below for the full report:

https://hardmanandco.com/research/corporate-research/shield-stx-november-2024-investor-forum/

If you are interested in meeting the company, you can register your interest by clicking on the above link.

Hardman & Co Research can be accessed for free under MiFID. Please click here to read the statement.

About Hardman & Co: Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259. Attention is drawn to the important disclaimers at the end of the report.